ArticleThe Journal of clinical investigation2002
Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23.
Article in The Journal of clinical investigation, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 93 citations in OpenAlex.
- Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study.Clinical and experimental immunology · 2009Trial
- Soluble antigen arrays provide increased efficacy and safety over free peptides for tolerogenic immunotherapy.Frontiers in immunology · 2024Article
- Contribution of the Microbiome, Environment, and Genetics to Mucosal Type 2 Immunity and Anaphylaxis in a Murine Food Allergy Model.Frontiers in allergy · 2022Article
- The yin/yang balance of the MHC-selfFrontiers in immunology · 2022Review
- Soluble Antigen Arrays Efficiently Deliver Peptides and Arrest Spontaneous Autoimmune Diabetes.Diabetes · 2021Article
- Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction.Scientific reports · 2019Article
- The presentation of neuroendocrine self-peptides in the thymus: an essential event for individual life and vertebrate survival.Annals of the New York Academy of Sciences · 2019Review
- Antigen-specific therapeutic approaches for autoimmunity.Nature biotechnology · 2019Review
- Hypersensitivity reactions to asparaginase in mice are mediated by anti-asparaginase IgE and IgG and the immunoglobulin receptors FcεRI and FcγRIII.Haematologica · 2019Article
- A Special Connection between γδ T Cells and Natural Antibodies?Archivum immunologiae et therapiae experimentalis · 2016Review
- Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.Nature nanotechnology · 2016Article
- Human IgE-independent systemic anaphylaxis.The Journal of allergy and clinical immunology · 2016Review
- Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model.Clinical and experimental immunology · 2015Article
- Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis.Expert review of vaccines · 2015Review
- Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Antigen-based immunotherapy for autoimmune disease: current status.ImmunoTargets and therapy · 2015Review
- γδ T cells recognize the insulin B:9-23 peptide antigen when it is dimerized through thiol oxidation.Molecular immunology · 2014Article
- Programming of neuroendocrine self in the thymus and its defect in the development of neuroendocrine autoimmunity.Frontiers in neuroscience · 2013Review
- Destabilization of peptide:MHC interaction induces IL-2 resistant anergy in diabetogenic T cells.Journal of autoimmunity · 2013Article
- LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases.Journal of vaccines & vaccination · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
There is evidence that amino acids 9-23 of the insulin B chain are a major target of anti-islet autoimmunity in type 1 diabetes. Administration of this peptide to NOD mice prevents diabetes, and phase I trials of an altered peptide ligand of B:9-23 are underway in humans. We were interested in long-term subcutaneous therapeutic administration of B:9-23 without adjuvant. To our initial surprise, the peptide consistently induced fatal anaphylaxis in NOD mice after 6 weeks of administration. Anaphylaxis could be blocked by a combination of antihistamine and platelet-activating factor antagonist (but neither alone) or by a combination of anti-IgG receptor and anti-IgE antibodies. High titers of anti-B:9-23 antibodies were induced within 3-4 weeks of immunization with the peptide. Peptide B:13-23 also induced anaphylaxis and was more potent than peptide B:9-23. Antibodies induced by peptide B:9-23 and peptide B:13-23 did not cross-react with each other. Thus, the insulin peptides B:9-23 and B:13-23, even when administered subcutaneously in the absence of adjuvant, can induce a dramatic humoral response leading to fatal anaphylaxis in NOD mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.